Transplant rejection

This study tests a drug called efgartigimod, given as a shot under the skin, for people who have antibody-mediated rejection after a kidney transplant. The trial includes 30 adults who received a kidney at least 6 months ago and have signs of rejection. Participants will receive …

This study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejecti…

This study tests whether high doses of vitamin C given through an IV can help people recover better after a liver transplant. About 90 adults having their first liver transplant will receive either vitamin C or a placebo for two days. The goal is to see if vitamin C reduces organ…

This study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…

This study tests a drug called felzartamab in people who received a kidney transplant and later developed antibody-mediated rejection (AMR), where the immune system attacks the new kidney. The drug targets immune cells that make harmful antibodies, aiming to reduce kidney damage …

This study tests whether extra telemedicine support (using a smartphone or tablet) can help kidney transplant recipients better manage their health and keep their new kidney working longer. About 384 people who received a kidney transplant in the last year will be split into two …

This study compares a simple blood test (Prospera) to the standard heart biopsy for monitoring rejection in heart transplant patients. About 250 adults waiting for or who have received a heart transplant will be randomly assigned to one of two monitoring methods. The goal is to s…

This phase 2 trial tests a drug called BIVV020 in 48 kidney transplant recipients. The goal is to see if it can prevent or treat antibody-mediated rejection, a common cause of transplant failure. Participants receive BIVV020 plus standard care, and researchers monitor rejection r…

This study tests whether adding Thymoglobulin to standard anti-rejection drugs helps prevent complications after a first heart transplant. About 60 adults will receive either standard therapy alone or standard therapy plus five days of Thymoglobulin. Researchers will check for si…

This study is testing a new drug called tegoprubart (AT-1501) to see if it is safe and effective for preventing kidney transplant rejection over several years. About 132 people who have already received a kidney transplant will receive either tegoprubart or the standard drug tacr…

This study follows 11 kidney transplant patients who received an experimental cell therapy called TX200-TR101 in an earlier trial. Researchers will monitor them for up to 15 years to check for long-term side effects and how well their transplanted kidney is doing. The goal is to …

This early study tests whether the drug belumosudil, given with donor stem cells, can help the body accept a new kidney without needing strong anti-rejection drugs for life. Sixteen adults with end-stage kidney disease will receive a living donor kidney and stem cell transplant, …

This phase 2 trial tests whether adding belumosudil (Rezurock) to standard care can prevent scarring in new kidney transplants. About 40 adults receiving their first or second kidney will be randomly assigned to get the drug or a placebo for a year. The study tracks serious side …

This registry follows 350 adult heart transplant patients whose donor hearts were kept alive and beating using the OCS Heart System before transplant. The goal is to see how well patients do one year after surgery. The device may allow more donor hearts to be used, especially tho…

This study is testing a blood test that looks at gene activity to predict the risk of kidney transplant rejection. Researchers will follow 550 kidney transplant recipients to see if the test can identify those at risk for early rejection or long-term damage. The goal is to help d…

This study is testing a blood test called AlloSure Lung in 550 lung transplant patients. The test looks for DNA from the donor lung in the patient's blood, which could signal rejection or infection. Researchers want to see how accurate the test is compared to standard monitoring.…

This study follows 4,000 people who have had a lung transplant to see how their lungs and overall health change over many years. Researchers will collect data from clinic visits, lung function tests, and surveys about daily activities and quality of life. The goal is to better un…

This study follows over 2,700 heart transplant recipients to see how well HeartCare testing services work in routine care. Researchers will track whether patients develop certain antibodies that may signal rejection. The goal is to understand if regular monitoring helps catch pro…

This study looks back at the medical records of 1,891 adults who received a kidney transplant at a Belgian hospital between 2004 and 2022. Researchers are collecting routine clinical and lab data to find patterns that predict transplant rejection or failure. The goal is to build …

This study tests better ways to detect early artery narrowing in new hearts after transplant, a condition called cardiac allograft vasculopathy (CAV). About 80 adult heart transplant patients will be followed within their first three months to compare advanced imaging and blood t…

This study is testing two blood tests, AlloSure and AlloMap, to see if they can detect organ rejection in people who have received a combined kidney and pancreas transplant. The goal is to find a less invasive way to monitor for rejection compared to the standard tissue biopsy. T…

This study follows about 4,200 lung transplant recipients in France to understand why some people develop serious complications like chronic lung allograft dysfunction (CLAD). Researchers will collect routine health data, lung function tests, and blood samples to build a model th…

This study looks at gene activity in blood cells from 30 kidney or lung transplant patients who have chronic rejection. Researchers want to find out why some patients improve with a treatment called extracorporeal photoapheresis (ECP) while others do not. The goal is to better un…

This study follows 300 patients with severe alcoholic hepatitis who receive early liver transplants, before the usual 6-month sobriety period. Researchers will track how many survive one year after transplant and how many return to drinking. The goal is to better understand the r…

This study looks at whether a blood test can help doctors know if treatment for kidney rejection is working in children who have had a kidney transplant. About 27 kids will give blood samples to check for special markers. The goal is to see if the blood test can predict and monit…

This study is testing whether a simple urine test can detect signs of kidney transplant rejection in children. Researchers are looking for specific molecules in urine that signal the body is attacking the new kidney. If the test works, it could help doctors spot problems early wi…

This study looks at whether a blood test measuring CK-18, a protein released when liver cells die, can spot organ rejection after a liver transplant. Currently, doctors use a liver biopsy, which involves inserting a needle into the body and carries risks. Researchers will collect…

This study aimed to see if a simple blood test could find blockages in the small blood vessels of the heart in people who have had a heart transplant. Participants would have had blood draws every three months for a year, and their medical records would have been reviewed for thr…

This study planned to create artificial intelligence tools that could diagnose kidney transplant rejection using urine tests instead of invasive biopsies. Researchers wanted to combine urine markers with standard medical data to make diagnosis safer and easier. However, the study…